South Korea-based Boryung Corporation is significantly enhancing its global oncology presence through a $205 million deal to acquire rights to Sanofi’s established chemotherapy, Taxotere (docetaxel), across nearly 20 markets. This strategic move not only reflects Boryung’s ambition to expand its therapeutic portfolio but also highlights the ongoing interest in repurposing legacy products within the pharmaceutical landscape.
Taxotere, a cornerstone in cancer treatment since its launch, has faced increasing competition from generics and biosimilars, prompting Boryung to seek new value in this well-known asset. By securing the rights, Boryung aims to leverage its existing distribution networks and market expertise to revitalize Taxotere’s presence, potentially leading to increased accessibility for patients and enhanced revenue streams for the company.
This acquisition underscores a broader trend in the industry where companies are looking to optimize their portfolios by acquiring established drugs that can be revitalized in new markets. For Boryung, this move could position the company as a key player in the oncology space, while also challenging competitors who have dominated the chemotherapy market.
Use the database as your supply chain compass →
